Alvotech
ALVOHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Alvotech focuses on Drug Manufacturers - Specialty & Generic services and products. Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The $1.17B market capitalization puts ALVO squarely in small-cap range for its industry. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Market Cap
$1.17B
Beta
0.19
P/E (TTM)
—
P/E (Fwd)
14.74
EPS (TTM)
$-0.30
EPS (Fwd)
$0.23
ROE
—
ROA
3.8%
Cash
$63.8M
Total Debt
$1.46B
Free CF
-$92.6M
52W Change
-59.9%
Annual Financials
Cash vs Debt
The company holds $63.8M in cash, though total debt stands at $1.46B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$92.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $83.0M (2022) to $586.3M (2025), reflecting a 606% increase over the period.
With a beta below 0.7, Alvotech typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ALVO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.